Regulus Therapeutics Inc - Asset Resilience Ratio
Regulus Therapeutics Inc (RGLS) has an Asset Resilience Ratio of 21.26% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Regulus Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Regulus Therapeutics Inc's Asset Resilience Ratio has changed over time. See Regulus Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Regulus Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Regulus Therapeutics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $15.91 Million | 21.26% |
| Total Liquid Assets | $15.91 Million | 21.26% |
Asset Resilience Insights
- Good Liquidity Position: Regulus Therapeutics Inc maintains a healthy 21.26% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Regulus Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Regulus Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Regulus Therapeutics Inc (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Regulus Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 44.25% | $37.25 Million | $84.18 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $30.75 Million | -- |
| 2022-12-31 | 31.96% | $14.93 Million | $46.72 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $68.45 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $27.93 Million | -- |
| 2017-12-31 | 59.83% | $46.55 Million | $77.81 Million | -0.94pp |
| 2016-12-31 | 60.77% | $61.17 Million | $100.66 Million | -8.77pp |
| 2015-12-31 | 69.54% | $98.10 Million | $141.08 Million | -1.85pp |
| 2014-12-31 | 71.39% | $122.42 Million | $171.48 Million | -6.78pp |
| 2013-12-31 | 78.17% | $96.20 Million | $123.06 Million | +22.58pp |
| 2012-12-31 | 55.59% | $57.55 Million | $103.52 Million | -11.96pp |
| 2011-12-31 | 67.56% | $28.97 Million | $42.88 Million | +11.41pp |
| 2010-12-31 | 56.15% | $33.52 Million | $59.70 Million | -- |
About Regulus Therapeutics Inc
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target o… Read more